Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2016; 7(5): 352-369
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.352
Role of Akt signaling in resistance to DNA-targeted therapy
Abolfazl Avan, Ravi Narayan, Elisa Giovannetti, Godefridus J Peters
Abolfazl Avan, Elisa Giovannetti, Godefridus J Peters, Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
Ravi Narayan, Department of Radiation Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
Author contributions: Avan A and Peters GJ designed of the study; Avan A did the literature search and prepared the initial version; Narayan R, Giovannetti E and Peters GJ contributed to the literature search and modified the paper; Peters GJ made final editing; all the authors critically read the last version and approved it.
Conflict-of-interest statement: There are no conflicts of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Dr. Godefridus J Peters, PhD, Professor, Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Telephone: +31-20-4442633 Fax: +31-20-4443844
Received: March 23, 2016
Peer-review started: March 24, 2016
First decision: May 16, 2016
Revised: June 25, 2016
Accepted: July 29, 2016
Article in press: August 1, 2016
Published online: October 10, 2016
Core Tip

Core tip: The Akt pathway plays an important role in resistance to several cytotoxic agents, targeted drugs and radiation. Exposure to these drugs will stimulate the Akt survival pathway leading to a decreased response to these drugs. In model systems inhibition of the Akt pathway enhanced the cytotoxicity of drugs like taxanes, antimetabolites, platinum analogs, several targeted drugs and radiation. Akt inhibitors offer a new opportunity to increase the efficacy of currently used drugs and of radiotherapy.